MSD Completes $5.3B Acquisition of Terns Pharmaceuticals

Why It Matters

The transaction expands Merck’s CML pipeline, giving it a differentiated asset in a market where patients need new options, while the short‑term earnings impact is offset by potential long‑term revenue growth.

Key Takeaways

• Merck paid $53 per share, acquiring 86% of Terns
• TERN-701 received FDA breakthrough‑therapy designation for CML
• Acquisition adds $5.8 bn R&D charge to 2026 results
• Expected EPS decline of $0.12 per share in 2026
• Merck’s AI partnership with Google Cloud includes $1 bn investment

Pulse Analysis

Chronic myeloid leukaemia (CML) remains a lucrative yet competitive oncology segment, with patients often developing resistance to first‑line tyrosine‑kinase inhibitors. Merck’s purchase of Terns Pharmaceuticals gives it direct control over TERN‑701, a novel oral BCR‑ABL1 inhibitor that targets the myristoyl pocket—a mechanism distinct from existing TKIs. By adding a breakthrough‑therapy‑designated drug to its portfolio, Merck can address the unmet need of patients who have failed two or more prior therapies, potentially capturing a high‑margin niche and strengthening its position against rivals such as Novartis and Bristol‑Myers Squibb.

TERN‑701’s breakthrough‑therapy status, granted by the FDA for Philadelphia chromosome‑positive CML without the T315I mutation, reflects promising early data from the Phase I/II CARDINAL trial. The allosteric approach may overcome resistance pathways that limit current treatments, offering a differentiated oral option that could be combined with existing TKIs. If Phase III results confirm efficacy and safety, the drug could command premium pricing and generate multi‑billion‑dollar revenues over its lifecycle, reinforcing Merck’s oncology growth strategy.

Financially, the acquisition will be recorded as an asset purchase, imposing a $5.8 bn R&D charge and reducing GAAP and non‑GAAP earnings per share by roughly $0.12 in 2026. While the short‑term hit is material, Merck anticipates that the long‑term upside from TERN‑701, coupled with a $1 bn AI partnership with Google Cloud, will accelerate drug development and operational efficiency. The AI collaboration aims to streamline data analytics and clinical trial design, potentially shortening time‑to‑market for TERN‑701 and future pipeline candidates, thereby enhancing shareholder value.

Deal Summary

Merck & Co (MSD) completed its acquisition of Terns Pharmaceuticals, buying all outstanding shares at $53 per share for roughly $5.3 billion, making Terns a wholly‑owned subsidiary and expanding MSD’s chronic myeloid leukaemia pipeline. The cash tender offer closed after the May 4, 2026 deadline, and the transaction will be treated as an asset acquisition with a $5.8 billion R&D charge in 2026.